Graft versus host disease (GvHD) is an immune-driven disorder caused by a complex interplay between the donor's and recipient ...

Australian researchers have demonstrated that the use of a new, less toxic drug combination after stem cell transplants for ...

Researchers at MD Anderson discussed the five possible approaches to treating graft-versus-host disease in a review article ...

A “game-changing” Australian blood cancer treatment triples patients chances of surviving, being cancer free and avoiding ...

Australian researchers have demonstrated that the use of a new, less toxic drug combination after stem cell transplants for leukaemia significantly ...

The BM12 CAST trial, a major clinical trial led by the Australasian Leukaemia & Lymphoma Group (ALLG) across New Zealand and Australian hospitals, will transform global blood stem cell transplant ...

Key companies, such as CSL Behring, Equillium, Biocon, and medac, are advancing their assets through late-stage graft versus host disease clinical trials, driving innovation in the graft versus ...